Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Background: HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or the emergence of acquired resistance is a persistent clinical problem. Here we report that neratinib, an irreversible pan-HER inhibitor, in combination with the multi-...

Descrición completa

Detalles Bibliográficos

Principais autores:	Neil T Conlon, Sandra Roche, Amira F Mahdi, Alacoque Browne, Laura Breen, Johanna Gaubatz, Justine Meiller, Fiona O'Neill, Lorraine O'Driscoll, Mattia Cremona, Bryan T Hennessy, Lisa D Eli, John Crown, Denis M Collins
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2024-11-01
Series:	Translational Oncology
Assuntos:	Breast cancer HER2-positive Targeted therapies Tyrosine kinase inhibitors Neratinib Dasatinib
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S1936523324002006
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!